In this article , we summarize available literature evidence on different chemotherapy agents used beyond the first-line , in locally advanced or MBC patients , including rechallenge with anthracyclines and taxanes , antimetabolite and antimicrotubule agents , such as vinorelbine , capecitabine , eribulin , ixabepilone , and the newest developed agents , such as vinflunine , irinotecan , and etirinotecan .
Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer. Despite the recent advances in the biological understanding of breast cancer (BC), chemotherapy still represents a key component in the armamentarium for this disease. Different agents are available as mono-chemotherapy options in patients with locally advanced or metastatic BC (MBC) who progress after a first- and second-line treatment with anthracyclines and taxanes. However, no clear indication exists on what the best option is in some populations, such as heavily pretreated, elderly patients, triple-negative BC (TNBC), and those who do not respond to the first-line therapy. In this article , we summarize available literature evidence on different chemotherapy agents used beyond the first-line , in locally advanced or MBC patients , including rechallenge with anthracyclines and taxanes , antimetabolite and antimicrotubule agents , such as vinorelbine , capecitabine , eribulin , ixabepilone , and the newest developed agents , such as vinflunine , irinotecan , and etirinotecan .
### Instruction:
            Given the context about compound efficacy for the given treatment mentioned within the input, mentioned the compounds 
            that can co-occur for the mentioned treatment

            ### Input:
            Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer. Despite the recent advances in the biological understanding of breast cancer (BC), chemotherapy still represents a key component in the armamentarium for this disease. Different agents are available as mono-chemotherapy options in patients with locally advanced or metastatic BC (MBC) who progress after a first- and second-line treatment with anthracyclines and taxanes. However, no clear indication exists on what the best option is in some populations, such as heavily pretreated, elderly patients, triple-negative BC (TNBC), and those who do not respond to the first-line therapy. In this article , we summarize available literature evidence on different chemotherapy agents used beyond the first-line , in locally advanced or MBC patients , including rechallenge with anthracyclines and taxanes , antimetabolite and antimicrotubule agents , such as vinorelbine , capecitabine , eribulin , ixabepilone , and the newest developed agents , such as vinflunine , irinotecan , and etirinotecan .

            ### Response:
            vinorelbine, capecitabine, ixabepilone, irinotecan
            